The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Feb. 20, 2015
Applicants:

Cancer Research Technology Limited, London, Greater London, GB;

Imperial Innovations Limited, London, Greater London, GB;

Emory University, Atlanta, GA (US);

Inventors:

Alexander Bondke, Caputh, DE;

Sebastian Kroll, London, GB;

Anthony Barrett, London, GB;

Matthew Fuchter, London, GB;

Brian Slafer, Lemont, IL (US);

Simak Ali, London, GB;

Charles Coombes, London, GB;

James Patrick Snyder, Atlanta, GA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61P 25/28 (2006.01); A61P 9/00 (2006.01); A61P 25/16 (2006.01); A61P 31/00 (2006.01); A61P 13/12 (2006.01); A61P 9/10 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01);
Abstract

Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.


Find Patent Forward Citations

Loading…